Browsing by Author "Harrigan, P Richard"

Now showing 1 - 2 of 2
  • Thumbnail Image
    ItemOpen Access
    Comparison of Population and 454 “Deep” Sequence Analysis for HIV Type 1 Tropism Versus the Original Trofile Assay in Non-B Subtypes
    (AIDS Research and Human Retroviruses, 2013-06) Lee, Guinevere Q; Harrigan, P Richard; Dong, Winnie; Poon, Art FY; Heera, Jayvant; Demarest, James; Rinehart, Alex; Chapman, Doug; Valdez, Hernan; Portsmouth, Simon
  • Thumbnail Image
    ItemOpen Access
    Reliable genotypic tropism tests for the major HIV-1 subtypes.
    (Scientific reports, 2015-02-25) Cashin, Kieran; Gray, Lachlan R; Harvey, Katherine L; Perez-Bercoff, Danielle; Lee, Guinevere Q; Sterjovski, Jasminka; Roche, Michael; Demarest, James F; Drummond, Fraser; Harrigan, P Richard; Churchill, Melissa J; Gorry, Paul R
    Over the past decade antiretroviral drugs have dramatically improved the prognosis for HIV-1 infected individuals, yet achieving better access to vulnerable populations remains a challenge. The principal obstacle to the CCR5-antagonist, maraviroc, from being more widely used in anti-HIV-1 therapy regimens is that the pre-treatment genotypic "tropism tests" to determine virus susceptibility to maraviroc have been developed primarily for HIV-1 subtype B strains, which account for only 10% of infections worldwide. We therefore developed PhenoSeq, a suite of HIV-1 genotypic tropism assays that are highly sensitive and specific for establishing the tropism of HIV-1 subtypes A, B, C, D and circulating recombinant forms of subtypes AE and AG, which together account for 95% of HIV-1 infections worldwide. The PhenoSeq platform will inform the appropriate use of maraviroc and future CCR5 blocking drugs in regions of the world where non-B HIV-1 predominates, which are burdened the most by the HIV-1 pandemic.